MCID: HYP810
MIFTS: 58

Hypereosinophilic Syndrome, Idiopathic

Categories: Genetic diseases, Blood diseases, Rare diseases

Aliases & Classifications for Hypereosinophilic Syndrome, Idiopathic

MalaCards integrated aliases for Hypereosinophilic Syndrome, Idiopathic:

Name: Hypereosinophilic Syndrome, Idiopathic 57 40
Idiopathic Hypereosinophilic Syndrome 59 29 55 6 73
Hypereosinophilic Syndrome, Idiopathic, Resistant to Imatinib 57 13 6
Hes 57

Characteristics:

Orphanet epidemiological data:

59

OMIM:

57
Inheritance:
somatic mutation
isolated cases

Miscellaneous:
occurs at age 20-50 years
considered a myeloproliferative disorder
usually fatal
more common in men (9:1 male:female ratio)


HPO:

32
hypereosinophilic syndrome, idiopathic:
Inheritance somatic mutation sporadic


Classifications:



External Ids:

OMIM 57 607685
Orphanet 59 ORPHA3260
ICD10 via Orphanet 34 D47.5
UMLS via Orphanet 74 C0206141
MedGen 42 C0206141
UMLS 73 C0206141

Summaries for Hypereosinophilic Syndrome, Idiopathic

MalaCards based summary : Hypereosinophilic Syndrome, Idiopathic, also known as idiopathic hypereosinophilic syndrome, is related to eosinophilic gastroenteritis and hypereosinophilic syndrome, and has symptoms including pruritus and myalgia. An important gene associated with Hypereosinophilic Syndrome, Idiopathic is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are ERK Signaling and Activation of cAMP-Dependent PKA. The drugs Omalizumab and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are splenomegaly and hepatomegaly

Description from OMIM: 607685

Related Diseases for Hypereosinophilic Syndrome, Idiopathic

Diseases related to Hypereosinophilic Syndrome, Idiopathic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 eosinophilic gastroenteritis 29.9 IL3 IL5
2 hypereosinophilic syndrome 29.6 FIP1L1 IL3 IL5 KIT PDGFRA PDGFRB
3 pdgfra-associated chronic eosinophilic leukemia 10.6 FIP1L1 PDGFRA
4 endomyocardial fibrosis 10.6 FIP1L1 PDGFRA
5 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.5 PDGFRA PDGFRB
6 reticular perineurioma 10.5 KIT PDGFRA
7 gastric leiomyosarcoma 10.4 KIT PDGFRA
8 sarcomatoid renal cell carcinoma 10.4 KIT PDGFRA
9 conventional fibrosarcoma 10.4 KIT PDGFRA
10 endometrial small cell carcinoma 10.4 KIT PDGFRA
11 pulmonary vein stenosis 10.4 KIT PDGFRA
12 spinal chordoma 10.4 PDGFRA PDGFRB
13 undifferentiated pleomorphic sarcoma 10.4 KIT PDGFRA
14 lung adenoid cystic carcinoma 10.4 KIT PDGFRA
15 carney triad 10.4 KIT PDGFRA
16 mesenchymal cell neoplasm 10.4 KIT PDGFRA
17 neurofibromatosis, type i 10.4 KIT PDGFRA
18 seborrheic infantile dermatitis 10.3 IL3 IL5
19 8p11 myeloproliferative syndrome 10.2 KIT PDGFRB
20 intrinsic asthma 10.2 IL3 IL5
21 atopic keratoconjunctivitis 10.2 IL3 IL5
22 piebald trait 10.2 KIT PDGFRA
23 warthin tumor 10.2 KIT TGFA
24 eosinophilic gastritis 10.2 IL3 IL5
25 loeffler endocarditis 10.2 FIP1L1 IL5 PDGFRA
26 pollen allergy 10.2 IL3 IL5
27 neurilemmoma 10.1 KIT PDGFRA
28 vascular cancer 10.1 KIT PDGFRB
29 primary hypereosinophilic syndrome 10.1 FIP1L1 PDGFRA PDGFRB
30 neurofibroma 10.1 KIT PDGFRA
31 corneal dystrophy, subepithelial mucinous 10.1 FIP1L1 PDGFRA PDGFRB
32 eosinophilic pneumonia 10.1 IL3 IL5
33 sm-ahnmd 10.0 FIP1L1 KIT PDGFRA
34 mast cell neoplasm 10.0 IL3 KIT
35 budd-chiari syndrome 10.0 FIP1L1 PDGFRA
36 chronic myelomonocytic leukemia 10.0 KIT PDGFRB
37 desmoid tumor 9.9 KIT PDGFRA PDGFRB
38 fibrosarcoma of bone 9.9 KIT PDGFRA PDGFRB
39 dermatofibrosarcoma protuberans 9.9 KIT PDGFRA PDGFRB
40 small cell carcinoma 9.9 KIT PDGFRA
41 gastrointestinal stromal tumor 9.9 KIT PDGFRA PDGFRB
42 testicular gonadoblastoma 9.9 KIT WT1
43 cystic nephroma 9.8 KIT WT1
44 spindle cell liposarcoma 9.8 KIT WT1
45 congenital mesoblastic nephroma 9.8 KIT WT1
46 keratoconjunctivitis 9.8 IL3 IL5
47 core binding factor acute myeloid leukemia 9.8 KIT WT1
48 dysgerminoma of ovary 9.8 KIT WT1
49 gonadoblastoma 9.8 KIT WT1
50 malignant mesenchymoma 9.7 KIT WT1

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome, Idiopathic:



Diseases related to Hypereosinophilic Syndrome, Idiopathic

Symptoms & Phenotypes for Hypereosinophilic Syndrome, Idiopathic

Symptoms via clinical synopsis from OMIM:

57
AbdomenSpleen:
splenomegaly

Skin Nails Hair Skin:
pruritus

Muscle Soft Tissue:
myalgia

Cardiovascular Heart:
restrictive cardiomyopathy
cardiac infiltration of eosinophils
endomyocardial fibrosis

Neurologic Peripheral Nervous System:
peripheral nervous system involvement

Immunology:
no concurrent parasitic infection
no concurrent allergies

Abdomen Liver:
hepatomegaly

Cardiovascular Vascular:
venous thrombosis

Respiratory Lung:
pulmonary infiltrates

Neurologic Central Nervous System:
paraspinal masses
cauda equina syndrome

Hematology:
sustained eosinophilia (greater than 1,500/cubic mm) for greater than 6 months
total white blood cell count less than 25,000/cubic mm with 30-70% eosinophils
bone marrow biopsy shows increased eosinophils without myeloblasts


Clinical features from OMIM:

607685

Human phenotypes related to Hypereosinophilic Syndrome, Idiopathic:

32 (show all 11)
# Description HPO Frequency HPO Source Accession
1 splenomegaly 32 HP:0001744
2 hepatomegaly 32 HP:0002240
3 pruritus 32 HP:0000989
4 venous thrombosis 32 HP:0004936
5 myalgia 32 HP:0003326
6 abnormality of the nervous system 32 HP:0000707
7 eosinophilia 32 HP:0001880
8 pulmonary infiltrates 32 HP:0002113
9 myeloproliferative disorder 32 HP:0005547
10 restrictive cardiomyopathy 32 HP:0001723
11 endocardial fibrosis 32 HP:0006685

UMLS symptoms related to Hypereosinophilic Syndrome, Idiopathic:


pruritus, myalgia

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.66 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.66 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.66 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.66 KIT TGFA WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.66 KIT
6 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.66 TGFA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.66 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.66 WT1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.66 WT1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.66 KIT WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.66 WT1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.66 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.66 WT1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.66 WT1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.66 WT1 KIT TGFA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.66 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.66 KIT

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome, Idiopathic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.77 PDGFRB TGFA IL5 KIT PDGFRA
2 immune system MP:0005387 9.73 PDGFRA PDGFRB TGFA WT1 IL5 KIT
3 embryo MP:0005380 9.72 PDGFRB WT1 IL5 KIT PDGFRA
4 muscle MP:0005369 9.55 PDGFRB TGFA WT1 KIT PDGFRA
5 neoplasm MP:0002006 9.26 PDGFRA WT1 IL5 KIT
6 reproductive system MP:0005389 9.1 PDGFRB TGFA WT1 IL5 KIT PDGFRA

Drugs & Therapeutics for Hypereosinophilic Syndrome, Idiopathic

Drugs for Hypereosinophilic Syndrome, Idiopathic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
4 Adrenergic Agents Phase 4,Phase 2
5 Adrenergic Agonists Phase 4,Phase 2
6 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
7 Adrenergic beta-Agonists Phase 4,Phase 2
8 Albuterol Phase 4,Phase 2
9 Anti-Allergic Agents Phase 4,Phase 2
10 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3
11 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
12 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3
13 Autonomic Agents Phase 4,Phase 3,Phase 2
14 Bronchodilator Agents Phase 4,Phase 2
15 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
16 Neurotransmitter Agents Phase 4,Phase 2
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Respiratory System Agents Phase 4,Phase 2,Phase 3
19 Tocolytic Agents Phase 4,Phase 2
20 Antiemetics Phase 4,Phase 3,Phase 2
21 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
22 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
24 glucocorticoids Phase 4,Phase 2,Phase 3
25 Hormone Antagonists Phase 4,Phase 2,Phase 3
26 Hormones Phase 4,Phase 2,Phase 3
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
28 Methylprednisolone acetate Phase 4,Phase 3
29 Methylprednisolone Hemisuccinate Phase 4,Phase 3
30 Neuroprotective Agents Phase 4,Phase 3
31 Prednisolone acetate Phase 4,Phase 3
32 Prednisolone hemisuccinate Phase 4,Phase 3
33 Prednisolone phosphate Phase 4,Phase 3
34 Protective Agents Phase 4,Phase 3,Phase 2
35
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
36
Daunorubicin Approved Phase 3 20830-81-3 30323
37
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
38
Thioguanine Approved Phase 3 154-42-7 2723601
39
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
40
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
41
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
42
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 3 53-03-2 5865
43 Bone Density Conservation Agents Phase 3
44 Calcium, Dietary Phase 3
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
49 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
50 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
2 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
3 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
4 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
9 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
10 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
11 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
12 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
13 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
14 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Recruiting NCT03306043 Phase 3 Mepolizumab
15 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
16 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
17 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
18 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Not yet recruiting NCT03470311 Phase 3
19 Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Terminated NCT00097370 Phase 3 mepolizumab
20 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
21 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
22 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
23 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
24 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
25 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Completed NCT00086658 Phase 2 mepolizumab
26 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
27 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
28 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Completed NCT00483067 Phase 2 2-CdA;Ara-C;G-CSF (Granulocyte colony-stimulating factor)
29 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
30 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
31 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
32 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed NCT00555581 Phase 2 Imatinib Mesylate
33 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
34 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
35 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
36 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
37 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
38 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
39 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
40 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
41 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
42 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
43 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
44 Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib Mesylate
45 Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy Recruiting NCT02071901 Phase 2 eltrombopag olamine
46 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
47 Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Recruiting NCT03469934 Phase 2 ANB020;Placebo
48 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Recruiting NCT02560610 Phase 2 OC000459;Placebo
49 Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02130882 Phase 2 benralizumab
50 Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02101138 Phase 2 Dexpramipexole

Search NIH Clinical Center for Hypereosinophilic Syndrome, Idiopathic

Genetic Tests for Hypereosinophilic Syndrome, Idiopathic

Genetic tests related to Hypereosinophilic Syndrome, Idiopathic:

# Genetic test Affiliating Genes
1 Idiopathic Hypereosinophilic Syndrome 29 PDGFRA

Anatomical Context for Hypereosinophilic Syndrome, Idiopathic

MalaCards organs/tissues related to Hypereosinophilic Syndrome, Idiopathic:

41
Myeloid, Bone, Bone Marrow, Liver, Lung, Skin, T Cells

Publications for Hypereosinophilic Syndrome, Idiopathic

Articles related to Hypereosinophilic Syndrome, Idiopathic:

(show top 50) (show all 204)
# Title Authors Year
1
A Case of Pulmonary Hypertension Associated with Idiopathic Hypereosinophilic Syndrome. ( 29794385 )
2018
2
Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome. ( 29780651 )
2018
3
Idiopathic hypereosinophilic syndrome manifesting with eosinophilic cholecystitis and recurrent gastroenteritis. ( 28378039 )
2017
4
Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay. ( 28577656 )
2017
5
When a death apparently associated to sexual assault is instead a natural death due to idiopathic hypereosinophilic syndrome: The importance of gamma-hydroxybutyric acid analysis in vitreous humor. ( 28527983 )
2017
6
The right atrium in idiopathic hypereosinophilic syndrome : Insights from the 3D speckle tracking echocardiographic MAGYAR-Path Study. ( 29234843 )
2017
7
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. ( 28495918 )
2017
8
Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia. ( 27294613 )
2016
9
Idiopathic Hypereosinophilic Syndrome Associated with Endomyocardial Fibrosis, Intracardiac Thrombi, Pulmonary and Skin Infiltration: A Case Report. ( 27617583 )
2016
10
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. ( 27174585 )
2016
11
Eosinophilic pleural effusion as a manifestation of idiopathic hypereosinophilic syndrome. ( 27185511 )
2016
12
Idiopathic hypereosinophilic syndrome presenting as angina pectoris: A case report. ( 27521535 )
2016
13
Idiopathic hypereosinophilic syndrome. ( 27728301 )
2016
14
Idiopathic hypereosinophilic syndrome presenting with severe vasculitis successfully treated with imatinib. ( 27803915 )
2016
15
Idiopathic hypereosinophilic syndrome resulting in distal aortic thromboembolism in a dog. ( 27723953 )
2016
16
A Rare Case of Aortic Valve Thrombosis in Patient with Idiopathic Hypereosinophilic Syndrome. ( 26435854 )
2015
17
A Case of Idiopathic Hypereosinophilic Syndrome Causing Mitral Valve Papillary Muscle Rupture. ( 26640733 )
2015
18
Tricuspid valve surgery in patients with idiopathic hypereosinophilic syndrome. ( 25472741 )
2015
19
Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. ( 26497854 )
2015
20
Endobronchial Involvement in Idiopathic Hypereosinophilic Syndrome. ( 26492606 )
2015
21
Pyoderma gangrenosum in association with microscopic colitis, idiopathic hypereosinophilic syndrome, selective IgE deficiency and diabetes mellitus. ( 25704069 )
2015
22
Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations and Flame Figures: A Spectrum of Eosinophilic Dermatoses Whose Features Overlap With Wells' Syndrome. ( 25839890 )
2015
23
Comparison of two leukocytapheresis protocols in a case of idiopathic hypereosinophilic syndrome. ( 26463664 )
2015
24
Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system. ( 25843450 )
2015
25
Recurrent native and prosthetic mitral valve thrombosis in idiopathic hypereosinophilic syndrome. ( 25076546 )
2014
26
Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma. ( 25621091 )
2014
27
Idiopathic hypereosinophilic syndrome with multiple organ infarction: improvement of the skin condition masking the course of disease. ( 24667633 )
2014
28
Response to corticosteroids and cytotoxic drugs in a case of idiopathic hypereosinophilic syndrome with predominantly elevated eosinophils and multiple clinical manifestations. ( 25332568 )
2014
29
Pediatric idiopathic hypereosinophilic syndrome with Gianotti-Crosti syndrome: a novel presentation. ( 24738625 )
2014
30
Imaging diagnosis for left ventricular thrombosis in idiopathic hypereosinophilic syndrome: two case reports. ( 25275526 )
2014
31
A case of idiopathic hypereosinophilic syndrome presenting with acute respiratory distress syndrome. ( 24404401 )
2014
32
Eosinophilic cystitis and idiopathic hypereosinophilic syndrome in an eight-year-old girl. ( 25394455 )
2014
33
Pneumothorax as the initial manifestation of idiopathic hypereosinophilic syndrome. ( 25441802 )
2014
34
Two cases of acute myelitis with idiopathic hypereosinophilic syndrome. ( 24849647 )
2014
35
An unusual case of idiopathic hypereosinophilic syndrome presenting with myopericarditis and a polypoid cardiac mass. ( 24769822 )
2014
36
Idiopathic hypereosinophilic syndrome presenting as severe Loeffler's endocarditis. ( 23681213 )
2013
37
A 66-year-old man with multiple cerebral and cerebellar infarcts due to idiopathic hypereosinophilic syndrome. ( 23916764 )
2013
38
An unusual presentation of idiopathic hypereosinophilic syndrome. ( 23880718 )
2013
39
Idiopathic hypereosinophilic syndrome in children: 3 cases with review of literature. ( 22740191 )
2013
40
Can ANCA differentiate eosinophilic granulomatosis with polyangiitis (Churg-Strauss) from idiopathic hypereosinophilic syndrome? ( 24144017 )
2013
41
Chromosomal mosaicism for inversion of chromosome 3(p25, p26) in a case of idiopathic hypereosinophilic syndrome (IHES). ( 24426336 )
2013
42
Bioprosthetic valve replacement in idiopathic hypereosinophilic syndrome with mitral valve involvement. ( 24001347 )
2013
43
Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients. ( 22988896 )
2013
44
Ocular involvement in idiopathic hypereosinophilic syndrome: a rare finding. ( 22496024 )
2012
45
Idiopathic hypereosinophilic syndrome presenting with cardiac tamponade. ( 22770997 )
2012
46
[Idiopathic hypereosinophilic syndrome in a child with fever and hepatomegaly]. ( 22374529 )
2012
47
Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs. ( 22367886 )
2012
48
Idiopathic hypereosinophilic syndrome revealed by encephalopathy. ( 22999560 )
2012
49
Unusual cause of acute mitral regurgitation: idiopathic hypereosinophilic syndrome. ( 22364989 )
2012
50
Idiopathic hypereosinophilic syndrome presenting with liver mass: Report of two cases: Idiopathic hypereosinophilic syndrome and liver mass. ( 22087129 )
2011

Variations for Hypereosinophilic Syndrome, Idiopathic

ClinVar genetic disease variations for Hypereosinophilic Syndrome, Idiopathic:

6
(show top 50) (show all 172)
# Gene Variation Type Significance SNP ID Assembly Location
1 PDGFRA NM_006206.5(PDGFRA): c.2021C> T (p.Thr674Ile) single nucleotide variant Pathogenic rs121908587 GRCh37 Chromosome 4, 55144547: 55144547
2 PDGFRA NM_006206.5(PDGFRA): c.2021C> T (p.Thr674Ile) single nucleotide variant Pathogenic rs121908587 GRCh38 Chromosome 4, 54278380: 54278380
3 PDGFRA NM_006206.5(PDGFRA): c.1135T> G (p.Leu379Val) single nucleotide variant Conflicting interpretations of pathogenicity rs199827643 GRCh38 Chromosome 4, 54270646: 54270646
4 PDGFRA NM_006206.5(PDGFRA): c.1135T> G (p.Leu379Val) single nucleotide variant Conflicting interpretations of pathogenicity rs199827643 GRCh37 Chromosome 4, 55136813: 55136813
5 PDGFRA NM_006206.5(PDGFRA): c.996C> T (p.Val332=) single nucleotide variant Benign/Likely benign rs142498442 GRCh38 Chromosome 4, 54267616: 54267616
6 PDGFRA NM_006206.5(PDGFRA): c.996C> T (p.Val332=) single nucleotide variant Benign/Likely benign rs142498442 GRCh37 Chromosome 4, 55133783: 55133783
7 PDGFRA NM_006206.5(PDGFRA): c.2778C> T (p.Tyr926=) single nucleotide variant Benign/Likely benign rs138519829 GRCh38 Chromosome 4, 54289012: 54289012
8 PDGFRA NM_006206.5(PDGFRA): c.2778C> T (p.Tyr926=) single nucleotide variant Benign/Likely benign rs138519829 GRCh37 Chromosome 4, 55155179: 55155179
9 PDGFRA NM_006206.5(PDGFRA): c.201C> T (p.Ser67=) single nucleotide variant Benign/Likely benign rs35805947 GRCh37 Chromosome 4, 55127413: 55127413
10 PDGFRA NM_006206.5(PDGFRA): c.201C> T (p.Ser67=) single nucleotide variant Benign/Likely benign rs35805947 GRCh38 Chromosome 4, 54261246: 54261246
11 PDGFRA NM_006206.5(PDGFRA): c.276G> A (p.Ala92=) single nucleotide variant Likely benign rs140725151 GRCh38 Chromosome 4, 54261321: 54261321
12 PDGFRA NM_006206.5(PDGFRA): c.276G> A (p.Ala92=) single nucleotide variant Likely benign rs140725151 GRCh37 Chromosome 4, 55127488: 55127488
13 PDGFRA NM_006206.5(PDGFRA): c.801A> G (p.Pro267=) single nucleotide variant Conflicting interpretations of pathogenicity rs55966236 GRCh38 Chromosome 4, 54267330: 54267330
14 PDGFRA NM_006206.5(PDGFRA): c.801A> G (p.Pro267=) single nucleotide variant Conflicting interpretations of pathogenicity rs55966236 GRCh37 Chromosome 4, 55133497: 55133497
15 PDGFRA NM_006206.5(PDGFRA): c.1320G> A (p.Thr440=) single nucleotide variant Benign/Likely benign rs56026726 GRCh37 Chromosome 4, 55138643: 55138643
16 PDGFRA NM_006206.5(PDGFRA): c.1320G> A (p.Thr440=) single nucleotide variant Benign/Likely benign rs56026726 GRCh38 Chromosome 4, 54272476: 54272476
17 PDGFRA NM_006206.5(PDGFRA): c.1731G> A (p.Pro577=) single nucleotide variant Benign/Likely benign rs55830582 GRCh37 Chromosome 4, 55141085: 55141085
18 PDGFRA NM_006206.5(PDGFRA): c.1731G> A (p.Pro577=) single nucleotide variant Benign/Likely benign rs55830582 GRCh38 Chromosome 4, 54274918: 54274918
19 PDGFRA NM_006206.5(PDGFRA): c.1891C> T (p.Pro631Ser) single nucleotide variant Likely benign rs199902153 GRCh38 Chromosome 4, 54277492: 54277492
20 PDGFRA NM_006206.5(PDGFRA): c.1891C> T (p.Pro631Ser) single nucleotide variant Likely benign rs199902153 GRCh37 Chromosome 4, 55143659: 55143659
21 PDGFRA NM_006206.5(PDGFRA): c.2742G> C (p.Arg914=) single nucleotide variant Conflicting interpretations of pathogenicity rs56384252 GRCh37 Chromosome 4, 55155033: 55155033
22 PDGFRA NM_006206.5(PDGFRA): c.2742G> C (p.Arg914=) single nucleotide variant Conflicting interpretations of pathogenicity rs56384252 GRCh38 Chromosome 4, 54288866: 54288866
23 PDGFRA NM_006206.5(PDGFRA): c.3156G> A (p.Thr1052=) single nucleotide variant Benign/Likely benign rs55996208 GRCh37 Chromosome 4, 55161325: 55161325
24 PDGFRA NM_006206.5(PDGFRA): c.3156G> A (p.Thr1052=) single nucleotide variant Benign/Likely benign rs55996208 GRCh38 Chromosome 4, 54295158: 54295158
25 PDGFRA NM_006206.5(PDGFRA): c.3228C> T (p.Ile1076=) single nucleotide variant Benign/Likely benign rs148629782 GRCh37 Chromosome 4, 55161397: 55161397
26 PDGFRA NM_006206.5(PDGFRA): c.3228C> T (p.Ile1076=) single nucleotide variant Benign/Likely benign rs148629782 GRCh38 Chromosome 4, 54295230: 54295230
27 PDGFRA NM_006206.5(PDGFRA): c.368-3C> T single nucleotide variant Likely benign rs55947416 GRCh38 Chromosome 4, 54263664: 54263664
28 PDGFRA NM_006206.5(PDGFRA): c.368-3C> T single nucleotide variant Likely benign rs55947416 GRCh37 Chromosome 4, 55129831: 55129831
29 PDGFRA NM_006206.5(PDGFRA): c.612T> C (p.Asn204=) single nucleotide variant Benign rs2229307 GRCh38 Chromosome 4, 54263911: 54263911
30 PDGFRA NM_006206.5(PDGFRA): c.612T> C (p.Asn204=) single nucleotide variant Benign rs2229307 GRCh37 Chromosome 4, 55130078: 55130078
31 PDGFRA NM_006206.5(PDGFRA): c.939T> G (p.Gly313=) single nucleotide variant Benign rs4358459 GRCh37 Chromosome 4, 55133726: 55133726
32 PDGFRA NM_006206.5(PDGFRA): c.939T> G (p.Gly313=) single nucleotide variant Benign rs4358459 GRCh38 Chromosome 4, 54267559: 54267559
33 PDGFRA NM_006206.5(PDGFRA): c.1701A> G (p.Pro567=) single nucleotide variant Benign rs1873778 GRCh37 Chromosome 4, 55141055: 55141055
34 PDGFRA NM_006206.5(PDGFRA): c.1701A> G (p.Pro567=) single nucleotide variant Benign rs1873778 GRCh38 Chromosome 4, 54274888: 54274888
35 PDGFRA NM_006206.5(PDGFRA): c.1809G> A (p.Ala603=) single nucleotide variant Benign rs10028020 GRCh38 Chromosome 4, 54277410: 54277410
36 PDGFRA NM_006206.5(PDGFRA): c.1809G> A (p.Ala603=) single nucleotide variant Benign rs10028020 GRCh37 Chromosome 4, 55143577: 55143577
37 PDGFRA NM_006206.5(PDGFRA): c.2472C> T (p.Val824=) single nucleotide variant Benign rs2228230 GRCh38 Chromosome 4, 54285873: 54285873
38 PDGFRA NM_006206.5(PDGFRA): c.2472C> T (p.Val824=) single nucleotide variant Benign rs2228230 GRCh37 Chromosome 4, 55152040: 55152040
39 PDGFRA NM_006206.5(PDGFRA): c.3222T> C (p.Asp1074=) single nucleotide variant Benign rs7685117 GRCh38 Chromosome 4, 54295224: 54295224
40 PDGFRA NM_006206.5(PDGFRA): c.3222T> C (p.Asp1074=) single nucleotide variant Benign rs7685117 GRCh37 Chromosome 4, 55161391: 55161391
41 PDGFRA NM_006206.5(PDGFRA): c.-104_-103delAG deletion Benign rs886059442 GRCh38 Chromosome 4, 54229324: 54229325
42 PDGFRA NM_006206.5(PDGFRA): c.-104_-103delAG deletion Benign rs886059442 GRCh37 Chromosome 4, 55095491: 55095492
43 PDGFRA NM_006206.5(PDGFRA): c.954A> G (p.Lys318=) single nucleotide variant Uncertain significance rs886059444 GRCh38 Chromosome 4, 54267574: 54267574
44 PDGFRA NM_006206.5(PDGFRA): c.954A> G (p.Lys318=) single nucleotide variant Uncertain significance rs886059444 GRCh37 Chromosome 4, 55133741: 55133741
45 PDGFRA NM_006206.5(PDGFRA): c.1122-6T> A single nucleotide variant Uncertain significance rs754623338 GRCh37 Chromosome 4, 55136794: 55136794
46 PDGFRA NM_006206.5(PDGFRA): c.1122-6T> A single nucleotide variant Uncertain significance rs754623338 GRCh38 Chromosome 4, 54270627: 54270627
47 PDGFRA NM_006206.5(PDGFRA): c.3191A> G (p.Asp1064Gly) single nucleotide variant Uncertain significance rs375050626 GRCh37 Chromosome 4, 55161360: 55161360
48 PDGFRA NM_006206.5(PDGFRA): c.3191A> G (p.Asp1064Gly) single nucleotide variant Uncertain significance rs375050626 GRCh38 Chromosome 4, 54295193: 54295193
49 PDGFRA NM_006206.5(PDGFRA): c.*51G> A single nucleotide variant Likely benign rs141346675 GRCh37 Chromosome 4, 55161490: 55161490
50 PDGFRA NM_006206.5(PDGFRA): c.*51G> A single nucleotide variant Likely benign rs141346675 GRCh38 Chromosome 4, 54295323: 54295323

Copy number variations for Hypereosinophilic Syndrome, Idiopathic from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 120036 18 19523559 19789027 Insertion LAMA3 Idiopathic hypereosinophilic syndrome
2 187722 4 53938619 54020599 Translate FIP1L1 Idiopathic hypereosinophilic syndrome

Expression for Hypereosinophilic Syndrome, Idiopathic

Search GEO for disease gene expression data for Hypereosinophilic Syndrome, Idiopathic.

Pathways for Hypereosinophilic Syndrome, Idiopathic

Pathways related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 IL3 IL5 KIT PDGFRA PDGFRB TGFA
2
Show member pathways
13.3 IL3 KIT PDGFRA PDGFRB TGFA
3
Show member pathways
13.24 IL3 IL5 KIT PDGFRA PDGFRB
4
Show member pathways
13.15 IL3 IL5 KIT PDGFRA PDGFRB TGFA
5
Show member pathways
13.11 IL3 IL5 KIT PDGFRA PDGFRB
6
Show member pathways
13.08 IL3 KIT PDGFRA PDGFRB TGFA
7
Show member pathways
13.04 IL3 KIT PDGFRA PDGFRB TGFA
8
Show member pathways
12.99 IL3 IL5 KIT PDGFRA PDGFRB TGFA
9
Show member pathways
12.8 IL3 KIT PDGFRA PDGFRB TGFA
10
Show member pathways
12.76 IL3 KIT PDGFRA PDGFRB TGFA
11
Show member pathways
12.7 IL3 IL5 KIT PDGFRA PDGFRB TGFA
12
Show member pathways
12.55 IL3 KIT PDGFRA PDGFRB TGFA
13 12.54 KIT PDGFRA PDGFRB TGFA
14
Show member pathways
12.5 KIT PDGFRA PDGFRB TGFA
15
Show member pathways
12.4 IL3 KIT PDGFRA PDGFRB TGFA
16
Show member pathways
12.39 IL3 IL5 PDGFRA PDGFRB
17
Show member pathways
12.24 IL5 PDGFRA PDGFRB
18
Show member pathways
12.19 KIT PDGFRA PDGFRB
19 11.88 IL3 PDGFRB WT1
20 11.82 IL3 IL5 KIT PDGFRA PDGFRB TGFA
21 11.79 IL3 IL5 KIT
22 11.7 IL3 IL5 KIT
23 11.65 PDGFRA PDGFRB TGFA
24 11.45 KIT PDGFRA PDGFRB
25 11.43 KIT PDGFRA PDGFRB TGFA
26 11.39 KIT PDGFRA
27
Show member pathways
11.37 KIT PDGFRA PDGFRB
28 11.34 IL3 KIT
29 11.34 IL3 IL5
30 11.3 PDGFRA PDGFRB
31 11.27 PDGFRA PDGFRB
32 11.09 IL3 IL5
33 10.97 PDGFRA PDGFRB
34 10.73 PDGFRA PDGFRB

GO Terms for Hypereosinophilic Syndrome, Idiopathic

Cellular components related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.26 KIT PDGFRA PDGFRB TGFA
2 intrinsic component of plasma membrane GO:0031226 9.16 PDGFRA PDGFRB
3 receptor complex GO:0043235 8.8 KIT PDGFRA PDGFRB

Biological processes related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.85 IL3 IL5 KIT
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 KIT PDGFRA PDGFRB
3 positive regulation of cell migration GO:0030335 9.83 KIT PDGFRA PDGFRB
4 protein autophosphorylation GO:0046777 9.81 KIT PDGFRA PDGFRB
5 positive regulation of protein kinase B signaling GO:0051897 9.8 KIT PDGFRA PDGFRB
6 positive regulation of MAPK cascade GO:0043410 9.79 KIT PDGFRA PDGFRB
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.77 KIT PDGFRA PDGFRB
8 negative regulation of signal transduction GO:0009968 9.77 KIT PDGFRA PDGFRB
9 negative regulation of apoptotic process GO:0043066 9.77 KIT PDGFRA PDGFRB TGFA WT1
10 male gonad development GO:0008584 9.76 KIT PDGFRB WT1
11 phosphatidylinositol phosphorylation GO:0046854 9.75 KIT PDGFRA PDGFRB
12 wound healing GO:0042060 9.71 PDGFRA PDGFRB TGFA
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 IL3 IL5 TGFA
14 cell chemotaxis GO:0060326 9.69 KIT PDGFRA PDGFRB
15 positive regulation of fibroblast proliferation GO:0048146 9.67 PDGFRA PDGFRB
16 phosphatidylinositol-mediated signaling GO:0048015 9.67 PDGFRA PDGFRB
17 positive regulation of kinase activity GO:0033674 9.67 KIT PDGFRA PDGFRB
18 positive regulation of DNA replication GO:0045740 9.66 IL3 PDGFRA
19 platelet-derived growth factor receptor signaling pathway GO:0048008 9.65 PDGFRA PDGFRB
20 positive regulation of mitotic nuclear division GO:0045840 9.65 PDGFRB TGFA
21 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 KIT PDGFRA PDGFRB
22 MAPK cascade GO:0000165 9.65 IL3 IL5 KIT PDGFRA PDGFRB
23 positive regulation of JAK-STAT cascade GO:0046427 9.64 IL5 KIT
24 adrenal gland development GO:0030325 9.63 PDGFRA WT1
25 male genitalia development GO:0030539 9.63 PDGFRA WT1
26 cardiac myofibril assembly GO:0055003 9.62 PDGFRA PDGFRB
27 embryonic hemopoiesis GO:0035162 9.61 IL3 KIT
28 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.57 PDGFRA PDGFRB
29 metanephric mesenchyme development GO:0072075 9.56 PDGFRB WT1
30 retina vasculature development in camera-type eye GO:0061298 9.55 PDGFRA PDGFRB
31 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.5 KIT PDGFRA PDGFRB
32 metanephric S-shaped body morphogenesis GO:0072284 9.46 PDGFRB WT1
33 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.43 PDGFRA PDGFRB
34 positive regulation of cell proliferation GO:0008284 9.43 IL3 IL5 KIT PDGFRA PDGFRB TGFA
35 metanephric glomerular capillary formation GO:0072277 9.4 PDGFRA PDGFRB
36 positive regulation of phospholipase C activity GO:0010863 9.33 KIT PDGFRA PDGFRB
37 peptidyl-tyrosine phosphorylation GO:0018108 9.02 IL3 IL5 KIT PDGFRA PDGFRB

Molecular functions related to Hypereosinophilic Syndrome, Idiopathic according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.67 IL3 IL5 TGFA
2 MAP kinase kinase kinase activity GO:0004709 9.61 KIT PDGFRA PDGFRB
3 mitogen-activated protein kinase kinase binding GO:0031434 9.58 KIT PDGFRA PDGFRB
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.54 KIT PDGFRA PDGFRB
5 platelet-derived growth factor receptor binding GO:0005161 9.48 PDGFRA PDGFRB
6 platelet-derived growth factor binding GO:0048407 9.46 PDGFRA PDGFRB
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 KIT PDGFRA PDGFRB
8 protein tyrosine kinase activity GO:0004713 9.35 IL3 IL5 KIT PDGFRA PDGFRB
9 growth factor binding GO:0019838 9.33 KIT PDGFRA PDGFRB
10 vascular endothelial growth factor binding GO:0038085 9.32 PDGFRA PDGFRB
11 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.02 IL3 IL5 KIT PDGFRA PDGFRB

Sources for Hypereosinophilic Syndrome, Idiopathic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....